Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iEuroEwing trial for treatment optimization in Ewing sarcoma
2019-004153-93Phase 3Active
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Jul 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vinorelbine, cyclophosphamide, doxorubicin and ifosfamide in Ewing sarcoma and Ewing-like sarcoma (2 arms), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Event-free survival. Started Jul 2021; status: active.
02
Drugs
vinorelbinecyclophosphamidedoxorubicinifosfamide
03
Conditions
Ewing sarcomaEwing-like sarcoma
Beyond the preview
Go deeper on 2019-004153-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004153-93.